CN1178955C - 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗 - Google Patents

经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗 Download PDF

Info

Publication number
CN1178955C
CN1178955C CNB988042142A CN98804214A CN1178955C CN 1178955 C CN1178955 C CN 1178955C CN B988042142 A CNB988042142 A CN B988042142A CN 98804214 A CN98804214 A CN 98804214A CN 1178955 C CN1178955 C CN 1178955C
Authority
CN
China
Prior art keywords
leu
tnfα
molecule
tnf alpha
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988042142A
Other languages
English (en)
Chinese (zh)
Other versions
CN1252809A (zh
Inventor
M��R��ղɭ
M·R·詹森
S·莫里生
H·艾尔斯纳
��������ķ������
I·达鲁姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affitech AS
Original Assignee
PHARMEXA AS
Farmaceutisk Laboratorium Ferring AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMEXA AS, Farmaceutisk Laboratorium Ferring AS filed Critical PHARMEXA AS
Publication of CN1252809A publication Critical patent/CN1252809A/zh
Application granted granted Critical
Publication of CN1178955C publication Critical patent/CN1178955C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB988042142A 1997-04-15 1998-04-15 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗 Expired - Fee Related CN1178955C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
DK0418/1997 1997-04-15
US4418797P 1997-04-24 1997-04-24
US60/044,187 1997-04-24

Publications (2)

Publication Number Publication Date
CN1252809A CN1252809A (zh) 2000-05-10
CN1178955C true CN1178955C (zh) 2004-12-08

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988042142A Expired - Fee Related CN1178955C (zh) 1997-04-15 1998-04-15 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗

Country Status (29)

Country Link
US (1) US7118750B1 (OSRAM)
EP (1) EP0975668B1 (OSRAM)
JP (1) JP2001521386A (OSRAM)
KR (1) KR100522289B1 (OSRAM)
CN (1) CN1178955C (OSRAM)
AR (1) AR012427A1 (OSRAM)
AT (1) ATE326481T1 (OSRAM)
AU (1) AU743400B2 (OSRAM)
BR (1) BR9811462A (OSRAM)
CA (1) CA2289476A1 (OSRAM)
CZ (1) CZ9903657A3 (OSRAM)
DE (1) DE69834556T2 (OSRAM)
DK (1) DK0975668T3 (OSRAM)
EE (1) EE9900461A (OSRAM)
ES (1) ES2264569T3 (OSRAM)
HR (1) HRP980203B1 (OSRAM)
HU (1) HUP0001930A3 (OSRAM)
IL (1) IL132281A0 (OSRAM)
NO (1) NO995002L (OSRAM)
NZ (1) NZ337955A (OSRAM)
PL (1) PL194221B1 (OSRAM)
RU (1) RU2241715C2 (OSRAM)
SI (1) SI0975668T1 (OSRAM)
SK (1) SK285639B6 (OSRAM)
TR (1) TR199902562T2 (OSRAM)
TW (1) TW510921B (OSRAM)
UA (1) UA72440C2 (OSRAM)
WO (1) WO1998046642A1 (OSRAM)
ZA (1) ZA983148B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
WO2000051637A1 (en) * 1999-03-02 2000-09-08 Centocor, Inc. ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
SK722002A3 (en) 1999-07-20 2003-02-04 Pharmexa As Method for down-regulating GDF-8 activity
WO2001097837A1 (en) * 2000-06-21 2001-12-27 Ferring Bv Solubilised protein vaccines
WO2003075951A2 (en) * 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
MXPA06009805A (es) 2004-02-27 2007-04-02 Vaxconsulting Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2011057099A2 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CA2820837A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
AU2016256876B2 (en) 2015-05-05 2021-02-04 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
TW510921B (en) 2002-11-21
HUP0001930A2 (hu) 2000-09-28
RU2241715C2 (ru) 2004-12-10
CA2289476A1 (en) 1998-10-22
KR20010006416A (ko) 2001-01-26
HRP980203A2 (en) 1998-12-31
UA72440C2 (en) 2005-03-15
PL336295A1 (en) 2000-06-19
EE9900461A (et) 2000-06-15
AR012427A1 (es) 2000-10-18
ES2264569T3 (es) 2007-01-01
CN1252809A (zh) 2000-05-10
HUP0001930A3 (en) 2001-10-29
AU743400B2 (en) 2002-01-24
ZA983148B (en) 1999-10-15
ATE326481T1 (de) 2006-06-15
JP2001521386A (ja) 2001-11-06
SK285639B6 (sk) 2007-05-03
PL194221B1 (pl) 2007-05-31
CZ9903657A3 (cs) 2001-09-12
TR199902562T2 (xx) 2000-02-21
AU7030398A (en) 1998-11-11
DE69834556T2 (de) 2007-05-10
NO995002L (no) 1999-12-15
US7118750B1 (en) 2006-10-10
BR9811462A (pt) 2000-09-12
HRP980203B1 (en) 2003-04-30
IL132281A0 (en) 2001-03-19
NO995002D0 (no) 1999-10-14
EP0975668A1 (en) 2000-02-02
SK140999A3 (en) 2000-06-12
WO1998046642A1 (en) 1998-10-22
NZ337955A (en) 2000-09-29
DE69834556D1 (de) 2006-06-22
HK1022918A1 (en) 2000-08-25
KR100522289B1 (ko) 2005-10-19
DK0975668T3 (da) 2006-09-25
EP0975668B1 (en) 2006-05-17
SI0975668T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
CN1227360C (zh) Mage家族肿瘤相关抗原衍生物及其编码核酸序列
CN1252809A (zh) 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗
CN1195849C (zh) April－具有生长效应的新的蛋白质
CN1318105A (zh) 负调节Osteoprotegerin配体活性的方法
CN1269832A (zh) K－配体－新的免疫系统蛋白
CN1283659C (zh) 截短的神经胶质细胞系来源的神经营养因子
CN1122613A (zh) 免疫原或诊断剂的制备及其获得免疫原或诊断试剂的方法
HK1048937A1 (zh) 下调gdf-8活性的方法
CN1960752A (zh) 非人类tnf－肽的载体偶联物的医药用途
CN1539970A (zh) 嗜中性白细胞因子α
CN1602201A (zh) 具有血小板生成活性的肽和相关的化合物
CN1675237A (zh) 免疫原性组合物
CN1256147C (zh) Cd8作为细胞免疫系统的抑制剂
CN1543504A (zh) 疫苗
CN1549726A (zh) 先天性免疫系统指导的疫苗
CN1867352A (zh) 趋化因子变体的治疗性应用
CN1741818A (zh) 线虫多肽佐剂
CN1688607A (zh) 包含支架,佐剂和抗原的异源多聚体化合物及其用途
CN1615316A (zh) 多聚体蛋白质的新免疫原性模拟物
CN1726283A (zh) 利用c4bp支架制备多聚体融合蛋白
CN1158387C (zh) 编码l.infantum的四种蛋白质的抗原决定簇的嵌合基因
CN1733918A (zh) 促胃动素同系物
CN1227359C (zh) 负调节抗性c3转化酶
CN1639569A (zh) 诱导免疫应答的方法和组合物
CN1867588A (zh) 包含c4bp核心蛋白质和单体抗原的产品及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: FARMERCO CO., LTD.

Free format text: FORMER OWNER: PHARMACEUTISK LABORATORIUM FERRING A/S

Effective date: 20031120

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20031120

Address after: Holm Hess, Denmark

Applicant after: Pharmexa AS

Address before: Denmark Lusi million

Applicant before: Pharmaceutisk Laboratorium Ferring A/S

C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee